Jeffrey Dunn, Pharm.D., MBA, discusses how comparison trials for different assisted reproductive technologies (ARTs) are necessary to evaluate their relative efficacy, safety and cost-effectiveness, with specific focus on a trial comparing highly purified human menotropin (HP-hMG) and recombinant follicle-stimulating hormone (FSH), as well as a study examining the impact of health benefit design for ART on pregnancy outcomes.
Video content above is prompted by the following:
Can Lecanemab Succeed Where Aduhelm Failed?
September 28th 2022The announcement of positive phase 3 results for the investigational Alzheimer’s disease drug comes against a backdrop of Aduhelm flaming out. Both drugs are predicated on the theory that Alzheimer’s is caused by beta-amyloid deposits.
Read More